Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
October 28, 2019
October 28, 2019
HOUSTON, Texas, Oct. 28 -- The University of Texas's MD Anderson Cancer Center issued the following news release:
Ziopharm Oncology, Inc., and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating to Ziopharm's Sleeping Beauty immunotherapy program to use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors (TCRs) in T cells (referred to as TCR-T).
"We ar . . .
Ziopharm Oncology, Inc., and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating to Ziopharm's Sleeping Beauty immunotherapy program to use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors (TCRs) in T cells (referred to as TCR-T).
"We ar . . .